Sarasin & Partners LLP Has $251.33 Million Position in Zoetis Inc. $ZTS

Key Points

• Sarasin & Partners LLP increased its stake in Zoetis Inc. by 3.7% during the second quarter, now owning 1,611,579 shares valued at approximately $251 million, making it the firm's 14th largest holding.
• Zoetis reported earnings of $1.76 per share for the last quarter, beating analyst estimates, with revenue growth of 4.2% year-over-year, totaling $2.46 billion.
• Analysts have been mixed on Zoetis, with a consensus rating of "Moderate Buy" and a price target averaging around $200.88, though recent reports have seen some downgrades in ratings and target prices.

Sarasin & Partners LLP boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 3.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,611,579 shares of the company's stock after purchasing an additional 57,724 shares during the period. Zoetis makes up approximately 2.5% of Sarasin & Partners LLP's holdings, making the stock its 14th largest position. Sarasin & Partners LLP owned about 0.36% of Zoetis worth $251,326,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Lindbrook Capital LLC raised its stake in shares of Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock valued at $612,000 after purchasing an additional 65 shares during the period. Quotient Wealth Partners LLC raised its stake in shares of Zoetis by 2.3% during the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after purchasing an additional 72 shares during the period. Broadway Wealth Solutions Inc. raised its stake in shares of Zoetis by 4.4% during the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock valued at $287,000 after purchasing an additional 73 shares during the period. Menard Financial Group LLC increased its stake in shares of Zoetis by 3.8% in the first quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock worth $305,000 after buying an additional 75 shares during the last quarter. Finally, Anchor Investment Management LLC increased its stake in shares of Zoetis by 4.9% in the first quarter. Anchor Investment Management LLC now owns 1,618 shares of the company's stock worth $266,000 after buying an additional 75 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

ZTS stock traded down $1.28 during midday trading on Friday, hitting $145.82. 4,455,824 shares of the company traded hands, compared to its average volume of 2,273,605. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $197.51. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The business has a 50 day simple moving average of $151.43 and a 200-day simple moving average of $156.76. The stock has a market capitalization of $64.63 billion, a price-to-earnings ratio of 25.10, a price-to-earnings-growth ratio of 2.36 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter last year, the company posted $1.56 earnings per share. Zoetis's quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler boosted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Argus reissued a "buy" rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Zoetis has an average rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.